Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 267

1.

Complement alone drives efficacy of a chimeric antigonococcal monoclonal antibody.

Gulati S, Beurskens FJ, de Kreuk BJ, Roza M, Zheng B, DeOliveira RB, Shaughnessy J, Nowak NA, Taylor RP, Botto M, He X, Ingalls RR, Woodruff TM, Song WC, Schuurman J, Rice PA, Ram S.

PLoS Biol. 2019 Jun 19;17(6):e3000323. doi: 10.1371/journal.pbio.3000323. eCollection 2019 Jun.

2.

Biology of the Gonococcus: Disease and Pathogenesis.

Shaughnessy J, Ram S, Rice PA.

Methods Mol Biol. 2019;1997:1-27. doi: 10.1007/978-1-4939-9496-0_1.

PMID:
31119614
3.

Targeting Lipooligosaccharide (LOS) for a Gonococcal Vaccine.

Gulati S, Shaughnessy J, Ram S, Rice PA.

Front Immunol. 2019 Feb 27;10:321. doi: 10.3389/fimmu.2019.00321. eCollection 2019. Review.

4.

Candida albicans Factor H Binding Molecule Hgt1p - A Low Glucose-Induced Transmembrane Protein Is Trafficked to the Cell Wall and Impairs Phagocytosis and Killing by Human Neutrophils.

Kenno S, Speth C, Rambach G, Binder U, Chatterjee S, Caramalho R, Haas H, Lass-Flörl C, Shaughnessy J, Ram S, Gow NAR, Orth-Höller D, Würzner R.

Front Microbiol. 2019 Jan 15;9:3319. doi: 10.3389/fmicb.2018.03319. eCollection 2018.

5.

Gene Expression Profiling Reveals Aberrant T-cell Marker Expression on Tumor Cells of Waldenström's Macroglobulinemia.

Hao M, Barlogie B, Tricot G, Liu L, Qiu L, Shaughnessy JD Jr, Zhan F.

Clin Cancer Res. 2019 Jan 1;25(1):201-209. doi: 10.1158/1078-0432.CCR-18-1435. Epub 2018 Oct 2.

6.

Human Factor H Domains 6 and 7 Fused to IgG1 Fc Are Immunotherapeutic against Neisseria gonorrhoeae.

Shaughnessy J, Lewis LA, Zheng B, Carr C, Bass I, Gulati S, DeOliveira RB, Gose S, Reed GW, Botto M, Rice PA, Ram S.

J Immunol. 2018 Nov 1;201(9):2700-2709. doi: 10.4049/jimmunol.1701666. Epub 2018 Sep 28.

PMID:
30266769
7.

Human IgG Increases Virulence of Streptococcus pyogenes through Complement Evasion.

Ermert D, Weckel A, Magda M, Mörgelin M, Shaughnessy J, Rice PA, Björck L, Ram S, Blom AM.

J Immunol. 2018 May 15;200(10):3495-3505. doi: 10.4049/jimmunol.1800090. Epub 2018 Apr 6.

8.

Factor H-IgG Chimeric Proteins as a Therapeutic Approach against the Gram-Positive Bacterial Pathogen Streptococcus pyogenes.

Blom AM, Magda M, Kohl L, Shaughnessy J, Lambris JD, Ram S, Ermert D.

J Immunol. 2017 Dec 1;199(11):3828-3839. doi: 10.4049/jimmunol.1700426. Epub 2017 Oct 30.

9.

William Edward Gallie (1882-1959): father of the Gallie wiring technique for atlantoaxial arthrodesis.

Dossani RH, Shaughnessy J, Kalakoti P, Nanda A.

J Neurosurg. 2018 Mar;128(3):938-941. doi: 10.3171/2016.12.JNS161224. Epub 2017 May 26.

PMID:
28548597
10.

Gonococcal lipooligosaccharide sialylation: virulence factor and target for novel immunotherapeutics.

Ram S, Shaughnessy J, de Oliveira RB, Lewis LA, Gulati S, Rice PA.

Pathog Dis. 2017 Jun 1;75(4). doi: 10.1093/femspd/ftx049.

11.

NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma.

Hao M, Franqui-Machin R, Xu H, Shaughnessy J Jr, Barlogie B, Roodman D, Quelle DE, Janz S, Tomasson MH, Sanderson RD, Qiu L, Frech I, Tricot G, Zhan F.

Leukemia. 2017 Jul;31(7):1648-1650. doi: 10.1038/leu.2017.115. Epub 2017 Apr 12. No abstract available.

12.

Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma.

Sawyer JR, Tian E, Shaughnessy JD Jr, Epstein J, Swanson CM, Stangeby C, Hale CL, Parr L, Lynn M, Sammartino G, Lukacs JL, Stein C, Bailey C, Zangari M, Davies FE, Van Rhee F, Barlogie B, Morgan GJ.

Leukemia. 2017 Mar;31(3):637-644. doi: 10.1038/leu.2016.253. Epub 2016 Oct 3.

13.

Utilizing complement evasion strategies to design complement-based antibacterial immunotherapeutics: Lessons from the pathogenic Neisseriae.

Ram S, Shaughnessy J, DeOliveira RB, Lewis LA, Gulati S, Rice PA.

Immunobiology. 2016 Oct;221(10):1110-23. doi: 10.1016/j.imbio.2016.05.016. Epub 2016 Jun 1. Review.

14.

Psammomatous Cavernous Malformation Presenting as Drug-Resistant Epilepsy: Case Illustration and Review of Literature.

Sharma K, Kalakoti P, Shaughnessy JE, De La Cruz N, Dossani RH, Zhu P, Gonzalez-Toledo E, Ledbetter C, Pinskton JB, Nanda A, Riel-Romero RM, Minagar A, Notarianni C, Sun H.

World Neurosurg. 2016 Sep;93:120-6. doi: 10.1016/j.wneu.2016.05.093. Epub 2016 Jun 7. Review.

PMID:
27283183
15.

Prognostic significance of HPV status in postoperative squamous-cell carcinoma of the head and neck.

Bertke MH, Shaughnessy JN, Forsthoefel MK, Cash LD, Silverman CL, Bumpous JM, Potts KL, Redman RA, Perez CA, Dunlap NE.

J Community Support Oncol. 2016 May;14(5):215-20. doi: 10.12788/jcso.0252.

PMID:
27258054
16.

Defining the Binding Region in Factor H to Develop a Therapeutic Factor H-Fc Fusion Protein against Non-Typeable Haemophilus influenzae.

Wong SM, Shaughnessy J, Ram S, Akerley BJ.

Front Cell Infect Microbiol. 2016 Apr 13;6:40. doi: 10.3389/fcimb.2016.00040. eCollection 2016.

17.

Stereotactic Radiosurgery as Part of Multimodal Treatment in a Bulky Leptomeningeal Recurrence of Breast Cancer.

Bertke MH, Burton EC, Shaughnessy JN.

Cureus. 2016 Mar 8;8(3):e523. doi: 10.7759/cureus.523.

18.

Cyclical hypofractionated radiotherapy technique for palliative treatment of locally advanced head and neck cancer: institutional experience and review of palliative regimens.

Finnegan TS, Bhatt NH, Shaughnessy JN, Perez C, Redman R, Silverman C, Bumpous J, Potts K, Dunlap NE.

J Community Support Oncol. 2016 Jan;14(1):29-36. doi: 10.12788/jcso.0201.

PMID:
26870840
19.

A Novel Factor H-Fc Chimeric Immunotherapeutic Molecule against Neisseria gonorrhoeae.

Shaughnessy J, Gulati S, Agarwal S, Unemo M, Ohnishi M, Su XH, Monks BG, Visintin A, Madico G, Lewis LA, Golenbock DT, Reed GW, Rice PA, Ram S.

J Immunol. 2016 Feb 15;196(4):1732-40. doi: 10.4049/jimmunol.1500292. Epub 2016 Jan 15.

20.

Allelic mutations in noncoding genomic sequences construct novel transcription factor binding sites that promote gene overexpression.

Tian E, Børset M, Sawyer JR, Brede G, Våtsveen TK, Hov H, Waage A, Barlogie B, Shaughnessy JD Jr, Epstein J, Sundan A.

Genes Chromosomes Cancer. 2015 Nov;54(11):692-701. doi: 10.1002/gcc.22280. Epub 2015 Jul 29.

21.

Virulence of Group A Streptococci Is Enhanced by Human Complement Inhibitors.

Ermert D, Shaughnessy J, Joeris T, Kaplan J, Pang CJ, Kurt-Jones EA, Rice PA, Ram S, Blom AM.

PLoS Pathog. 2015 Jul 22;11(7):e1005043. doi: 10.1371/journal.ppat.1005043. eCollection 2015 Jul.

22.

Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma.

Khan R, Apewokin S, Grazziutti M, Yaccoby S, Epstein J, van Rhee F, Rosenthal A, Waheed S, Usmani S, Atrash S, Kumar S, Hoering A, Crowley J, Shaughnessy JD Jr, Barlogie B.

Leukemia. 2015 May;29(5):1195-201. doi: 10.1038/leu.2015.15. Epub 2012 Feb 2.

23.

Efficacy of concurrent chemoradiotherapy for patients with locally recurrent or advanced inoperable breast cancer.

Shaughnessy JN, Meena RA, Dunlap NE, Jain D, Riley EC, Quillo AR, Dragun AE.

Clin Breast Cancer. 2015 Apr;15(2):135-42. doi: 10.1016/j.clbc.2014.10.007. Epub 2014 Oct 22.

PMID:
25454741
24.

Heterogeneity in rhesus macaque complement factor H binding to meningococcal factor H binding protein (FHbp) informs selection of primates to assess immunogenicity of FHbp-based vaccines.

Beernink PT, Shaughnessy J, Stefek H, Ram S, Granoff DM.

Clin Vaccine Immunol. 2014 Nov;21(11):1505-11. doi: 10.1128/CVI.00517-14. Epub 2014 Sep 3.

25.

Fusion protein comprising factor H domains 6 and 7 and human IgG1 Fc as an antibacterial immunotherapeutic.

Shaughnessy J, Vu DM, Punjabi R, Serra-Pladevall J, DeOliveira RB, Granoff DM, Ram S.

Clin Vaccine Immunol. 2014 Oct;21(10):1452-9. doi: 10.1128/CVI.00444-14. Epub 2014 Aug 20.

26.

CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease.

Johnson SK, Stewart JP, Bam R, Qu P, Barlogie B, van Rhee F, Shaughnessy JD Jr, Epstein J, Yaccoby S.

Blood. 2014 Sep 25;124(13):2051-60. doi: 10.1182/blood-2014-02-555813. Epub 2014 Jul 24.

27.

Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use.

van Laar R, Flinchum R, Brown N, Ramsey J, Riccitelli S, Heuck C, Barlogie B, Shaughnessy JD Jr.

BMC Med Genomics. 2014 May 17;7:25. doi: 10.1186/1755-8794-7-25.

28.

Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).

Dhodapkar MV, Sexton R, Waheed S, Usmani S, Papanikolaou X, Nair B, Petty N, Shaughnessy JD Jr, Hoering A, Crowley J, Orlowski RZ, Barlogie B.

Blood. 2014 Jan 2;123(1):78-85. doi: 10.1182/blood-2013-07-515239. Epub 2013 Oct 21.

29.

Factor H-dependent alternative pathway inhibition mediated by porin B contributes to virulence of Neisseria meningitidis.

Lewis LA, Vu DM, Vasudhev S, Shaughnessy J, Granoff DM, Ram S.

MBio. 2013 Oct 15;4(5):e00339-13. doi: 10.1128/mBio.00339-13.

30.

HPV: a factor in organ preservation for locally advanced larynx and hypopharynx cancer?

Shaughnessy JN, Farghaly H, Wilson L, Redman R, Potts K, Bumpous J, Silverman C, Dunlap NE.

Am J Otolaryngol. 2014 Jan-Feb;35(1):19-24. doi: 10.1016/j.amjoto.2013.08.006. Epub 2013 Oct 9.

PMID:
24119488
31.

TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity.

Gatt ME, Takada K, Mani M, Lerner M, Pick M, Hideshima T, Carrasco DE, Protopopov A, Ivanova E, Sangfelt O, Grandér D, Barlogie B, Shaughnessy JD Jr, Anderson KC, Carrasco DR.

Br J Haematol. 2013 Jul;162(2):210-20. doi: 10.1111/bjh.12365. Epub 2013 May 7.

32.

Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease.

Bam R, Ling W, Khan S, Pennisi A, Venkateshaiah SU, Li X, van Rhee F, Usmani S, Barlogie B, Shaughnessy J, Epstein J, Yaccoby S.

Am J Hematol. 2013 Jun;88(6):463-71. doi: 10.1002/ajh.23433. Epub 2013 Mar 28.

33.

Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levels.

Stone K, Woods E, Szmania SM, Stephens OW, Garg TK, Barlogie B, Shaughnessy JD Jr, Hall B, Reddy M, Hoering A, Hansen E, van Rhee F.

PLoS One. 2013;8(1):e54610. doi: 10.1371/journal.pone.0054610. Epub 2013 Jan 23.

34.

Developing and validating continuous genomic signatures in randomized clinical trials for predictive medicine.

Matsui S, Simon R, Qu P, Shaughnessy JD Jr, Barlogie B, Crowley J.

Clin Cancer Res. 2012 Nov 1;18(21):6065-73. doi: 10.1158/1078-0432.CCR-12-1206. Epub 2012 Aug 27.

35.

Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1.

Heuck CJ, Szymonifka J, Hansen E, Shaughnessy JD Jr, Usmani SZ, van Rhee F, Anaissie E, Nair B, Waheed S, Alsayed Y, Petty N, Bailey C, Epstein J, Hoering A, Crowley J, Barlogie B.

Clin Cancer Res. 2012 Oct 1;18(19):5499-506. doi: 10.1158/1078-0432.CCR-12-0019. Epub 2012 Aug 1. Erratum in: Clin Cancer Res. 2013 Feb 1;19(3):752.

36.

Proteasome inhibitors and bone disease.

Qiang YW, Heuck CJ, Shaughnessy JD Jr, Barlogie B, Epstein J.

Semin Hematol. 2012 Jul;49(3):243-8. doi: 10.1053/j.seminhematol.2012.04.011. Review.

37.

Proteasome inhibitors: introduction.

Heuck CJ, Shaughnessy JD Jr.

Semin Hematol. 2012 Jul;49(3):193-5. doi: 10.1053/j.seminhematol.2012.05.001. No abstract available.

PMID:
22726541
38.

The effect of human factor H on immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein.

Beernink PT, Shaughnessy J, Pajon R, Braga EM, Ram S, Granoff DM.

PLoS Pathog. 2012;8(5):e1002688. doi: 10.1371/journal.ppat.1002688. Epub 2012 May 10.

39.

Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols.

Usmani SZ, Nair B, Qu P, Hansen E, Zhang Q, Petty N, Waheed S, Shaughnessy JD Jr, Alsayed Y, Heuck CJ, van Rhee F, Milner T, Hoering A, Szymonifka J, Sexton R, Sawyer J, Singh Z, Crowley J, Barlogie B.

Leukemia. 2012 Nov;26(11):2398-405. doi: 10.1038/leu.2012.107. Epub 2012 Apr 17.

40.

Prediction of cytogenetic abnormalities with gene expression profiles.

Zhou Y, Zhang Q, Stephens O, Heuck CJ, Tian E, Sawyer JR, Cartron-Mizeracki MA, Qu P, Keller J, Epstein J, Barlogie B, Shaughnessy JD Jr.

Blood. 2012 May 24;119(21):e148-50. doi: 10.1182/blood-2011-10-388702. Epub 2012 Apr 10.

41.

Highly activated and expanded natural killer cells for multiple myeloma immunotherapy.

Garg TK, Szmania SM, Khan JA, Hoering A, Malbrough PA, Moreno-Bost A, Greenway AD, Lingo JD, Li X, Yaccoby S, Suva LJ, Storrie B, Tricot G, Campana D, Shaughnessy JD Jr, Nair BP, Bellamy WT, Epstein J, Barlogie B, van Rhee F.

Haematologica. 2012 Sep;97(9):1348-56. doi: 10.3324/haematol.2011.056747. Epub 2012 Mar 14.

42.

Maximum predictive power of the microarray-based models for clinical outcomes is limited by correlation between endpoint and gene expression profile.

Zhao C, Shi L, Tong W, Shaughnessy JD Jr, Oberthuer A, Pusztai L, Deng Y, Symmans WF, Shi T.

BMC Genomics. 2011 Dec 23;12 Suppl 5:S3. doi: 10.1186/1471-2164-12-S5-S3. Epub 2011 Dec 23.

43.

Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma.

Alapat D, Coviello-Malle J, Owens R, Qu P, Barlogie B, Shaughnessy JD, Lorsbach RB.

Am J Clin Pathol. 2012 Jan;137(1):93-100. doi: 10.1309/AJCP59UORCYZEVQO.

44.

Overview of biological database mapping services for interoperation between different 'omics' datasets.

Chavan SS, Shaughnessy JD Jr, Edmondson RD.

Hum Genomics. 2011 Oct;5(6):703-8. Review.

45.

Enhanced bacteremia in human factor H transgenic rats infected by Neisseria meningitidis.

Vu DM, Shaughnessy J, Lewis LA, Ram S, Rice PA, Granoff DM.

Infect Immun. 2012 Feb;80(2):643-50. doi: 10.1128/IAI.05604-11. Epub 2011 Nov 21.

46.

Self-generated retrievals while multitasking improve memory for names.

Helder E, Shaughnessy JJ.

Memory. 2011 Nov;19(8):968-74. doi: 10.1080/09658211.2011.626426.

PMID:
22092103
47.

An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification.

Stephens OW, Zhang Q, Qu P, Zhou Y, Chavan S, Tian E, Williams DR, Epstein J, Barlogie B, Shaughnessy JD Jr.

Blood. 2012 Jan 12;119(2):503-12. doi: 10.1182/blood-2011-07-367052. Epub 2011 Nov 9.

48.

The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma.

Johnson SK, Heuck CJ, Albino AP, Qu P, Zhang Q, Barlogie B, Shaughnessy JD Jr.

Int J Hematol. 2011 Oct;94(4):321-333. doi: 10.1007/s12185-011-0948-y. Epub 2011 Oct 15. Review.

49.

Ribosomal protein metallopanstimulin-1 impairs multiple myeloma CAG cells growth and inhibits fibroblast growth factor receptor 3.

Dai Y, Pierson S, Dudney C, Zeng Y, Macleod V, Shaughnessy JD, Stack BC Jr.

Clin Lymphoma Myeloma Leuk. 2011 Dec;11(6):490-7. doi: 10.1016/j.clml.2011.06.015. Epub 2011 Sep 1.

50.

Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone.

Li X, Ling W, Pennisi A, Wang Y, Khan S, Heidaran M, Pal A, Zhang X, He S, Zeitlin A, Abbot S, Faleck H, Hariri R, Shaughnessy JD Jr, van Rhee F, Nair B, Barlogie B, Epstein J, Yaccoby S.

Stem Cells. 2011 Feb;29(2):263-73. doi: 10.1002/stem.572.

Supplemental Content

Loading ...
Support Center